多发性骨髓瘤(multiple myeloma,MM)是目前无法治愈的浆细胞恶性增殖性血液系统肿瘤,老年人群好发,其发病率居血液肿瘤第2位~([1])。自体移植和新药(免疫调节药和蛋白酶体抑制药)的应用使患者的生存期得到了明显改善,老年MM的治疗也转变为一种新药联合化疗或地塞米松的思路。近年来,因明确MM的发病机制与骨髓微环境中的血管内皮系统密切相关,抗血管新生药物沙 Multiple myeloma (MM) is an incurable plasma cell malignant proliferative hematopoietic tumor at present. The incidence of this disease is high in the elderly and ranks the second in hematological malignancies [1]. Autologous transplantation and the use of new drugs (immunomodulators and proteasome inhibitors) have led to a significant improvement in patients’ survival, and the treatment of elderly MM has also been transformed into a new drug combination of chemotherapy or dexamethasone. In recent years, because of the clear pathogenesis of MM and the microvascular environment in the vascular endothelial system is closely related to anti-angiogenic drugs sand